RCM
BLACU

Radcliffe Capital Management’s Bellevue Life Sciences Acquisition Corp. Unit BLACU Stock Holding History

Radcliffe Capital Management’s Portfolio BLACU Stock Details BLACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-150,000
Closed -$1.55M – 591
2023
Q1 		$1.55M Buy
+150,000
New +$1.54M 0.1% 249

Other funds holding BLACU

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
TAM
Terrapin Asset Management Miami, Florida $87.8M AUM 16.84% 1-Year Est. Return

Radcliffe Capital Management's BLACU Position: Q2 2023 in Review

Radcliffe Capital Management sold out of Bellevue Life Sciences Acquisition Corp. Unit (BLACU) in Q2 2023, closing a stake of 150,000 shares — an estimated $1.55M sold.

Radcliffe Capital Management first reported a position in BLACU in Q1 2023 and held it in 1 quarter. The position peaked at $1.55M in Q1 2023. 13 funds tracked by Wall St. Rank hold BLACU as of Q2 2023.

  • Radcliffe Capital Management reported no remaining Bellevue Life Sciences Acquisition Corp. Unit position as of Q2 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 150,000 Bellevue Life Sciences Acquisition Corp. Unit shares in Q2 2023, an estimated $1.55M.
  • Radcliffe Capital Management first reported a position in Bellevue Life Sciences Acquisition Corp. Unit in Q1 2023 and held it in 1 quarter.
  • Radcliffe Capital Management's Bellevue Life Sciences Acquisition Corp. Unit position peaked at $1.55M in Q1 2023.
  • 13 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Unit as of Q2 2023.

Based on Radcliffe Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.